Search results for: 'android ed point termin forecast 2014'

This study provides an overview of the global point-of-care testing (POCT) industry, which refers to any routine or specialized lab pathology testing conducted rapidly, on-site/near the site of the patient, where care or treatment is provided. COVID-19 radicalization is changing the global diagnostics landscape. Consolidation trends, structural s...

14 Jul 2022  |  North America  |  Market Research

United States Molecular Point-of-Care Testing Growth Opportunities

Syndromic Point-of-Care Testing Drives Transformational Growth in Infectious Disease Diagnostics

Infographics

×

Rapid advancements in infectious disease diagnostics continue with novel identification methods and healthcare accessibility improvements. The shift from traditional testing to a more technologically empowered, consumer-centric testing encompasses the sample-in-answer-out approach of diagnostic testing that generates results in minutes or hours. Nu...

Cardiac troponin (cTn) biomarkers are the gold standard in myocardial infarction (MI) diagnosis, leading healthcare professionals to use cTn diagnostics. In addition, a rising number of patients visit emergency departments (EDs) with cardiac complaints, increasing ED demand for kits that can rapidly rule MI in or out. Both factors serve as signif...

23 Jun 2016  |  North America  |  Market Research

Growth Opportunities in the US Point-of-care Testing Market

Digital Health Meets Point of Care—Emergence of Mobile Molecular Diagnostics

Infographics

×

The US point-of-care testing (POCT) study provides an extensive analysis for 13 segments: hematology, urinalysis, infectious disease, cardiac, HbA1c, glucose, fecal occult blood test/fecal immunochemical test (FOBT/FIT), coagulation PT/INR, coagulation APTT/ACT, cholesterol, pregnancy, drugs of abuse, and blood gas and electrolytes. Key trends and ...

The main objective of this research is to estimate test volumes and unit prices for a wide variety of LDTs (genetic) and a few high volume FDA tests for selective therapeutic areas. The tests are categorized by their intended uses across the diagnostic spectrum (risk assessment, screening, diagnosis, staging and prognosis, therapy selection, therap...

This research service analyzes the market for point-of-care testing within the United States. The market is divided into 13 segments and covers testing performed by healthcare professionals in the physician office lab, hospital, clinics, and patient self-testing environments. Each segment covers the market overview, competitive structure, market s...

Management of infectious diseases remains a critical challenge for public health professionals who face increasing demand to control the spread of existing and novel diseases. To provide appropriate healthcare assistance, it is imperative to diagnose the exact form of infection from an array of complicated symptoms expressed by the host. As the out...

Since the onset of the COVID-19 pandemic, molecular diagnostics mergers/acquisition transactions and product launches for infectious disease testing are indicating a pivot toward a new direction or an enhancement of portfolios. The emergence of saliva sample testing and the transition to PCR-based syndromic and direct-to-consumer testing for respir...

In November 2013, Frost & Sullivan conducted an online survey, followed by a live focus group comprising C-suite executives from leading commercial healthcare payer organizations across the United States. The goal was to gain insights into how the health insurance industry approaches the use of analytics solutions going into 2014. For research purp...